论文部分内容阅读
FDA最近批准口服奥柳氮用于不能耐受柳氮磺胺吡啶及其它药物的成年溃疡性结肠炎患者进行持续治疗。药理奥柳氮是5-ASA(5-氨基水杨酸)的二聚体。5-ASA在结肠表面有效,而不是通过全身起作用。单纯的5-ASA(非二聚体)口服后多半在上消化道吸收或灭活,而不能到达结肠。奥柳氮仅约2%被吸收,大部分5-ASA在结肠内与细菌作用后才排出。临床试验在一项随机对照治疗试验中,7例轻～中度的溃疡性结肠炎患者用奥柳氮(每天3 g 4周)治疗后,有4例在临床症状上和直肠镜检时均有改善;1例无效,2例因严重腹泻而中止试验。8例给予安慰剂治
FDA recently approved Oral Ozone for sustained treatment of adult patients with ulcerative colitis who can not tolerate sulfasalazine and other drugs. Pharmacology Oruzin is a dimer of 5-ASA (5-aminosalicylic acid). 5-ASA is effective on the colon surface, rather than acting systemically. Simple 5-ASA (non-dimer) after oral administration mostly in the upper digestive tract absorption or inactivation, but can not reach the colon. Only about 2% of olivoside is absorbed, and most of the 5-ASA is excreted in the colon with bacteria. Clinical Trials In a randomized controlled trial of four patients with mild-to-moderate ulcerative colitis treated with orostatin (4 g daily for 4 weeks), 4 were clinically symptomatic and undergoing microscopic examinations There was improvement; one case was ineffective and two cases discontinued due to severe diarrhea. Eight patients received placebo